Neurofilament Light chain Antibodies

Neurofilament light chain (NfL) is a well‑established biomarker of neuro-axonal injury, reflected in both cerebrospinal fluid (CSF) and plasma by elevated concentrations^1,2. Neuro-axonal injury underlies permanent disability in various neurological conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia or Alzheimer’s disease, as well as acute situations such as traumatic brain injury and others. In Alzheimer’s disease, increased plasma and CSF NfL levels are associated with greater neurodegenerative burden and correlate with clinical progression, including future cognitive decline, brain atrophy, and hypometabolism³. More recent studies confirm that plasma NfL is negatively associated with global cognition and multiple cognitive domains and can track cognitive decline over time in neurodegenerative conditions, including Alzheimer’s disease⁴.

The ADx206 and ADx209 monoclonal antibodies targeting the Neurofilament Light chain protein can be used for the development of immunoassays measuring NfL.